These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 18158970)

  • 1. Continuing erythropoietin during peripheral blood stem cell collection in myeloma: can it reduce toxicity of autologous transplants?
    Labonté L; Iqbal T; McDiarmid S; Bence-Bruckler I; Huebsch L; Allan D
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):132-3. PubMed ID: 18158970
    [No Abstract]   [Full Text] [Related]  

  • 2. Autologous stem cell transplants in Jehovah's Witnesses.
    Brown NM; Kim SY; Ford PA
    Bone Marrow Transplant; 2009 Sep; 44(6):391-2. PubMed ID: 19308040
    [No Abstract]   [Full Text] [Related]  

  • 3. Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma.
    Nakasone H; Kanda Y; Ueda T; Matsumoto K; Shimizu N; Minami J; Sakai R; Hagihara M; Yokota A; Oshima K; Tsukada Y; Tachibana T; Nakaseko C; Fujisawa S; Yano S; Fujita H; Takahashi S; Kanamori H; Okamoto S;
    Am J Hematol; 2009 Dec; 84(12):809-14. PubMed ID: 19862826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells.
    Hart C; Grassinger J; Andreesen R; Hennemann B
    Bone Marrow Transplant; 2009 Feb; 43(3):197-206. PubMed ID: 18806833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemophagocytic syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma; successful treatment with high-dose intravenous immunoglobulin.
    Ostronoff M; Ostronoff F; Coutinho M; Calixto R; Souto Maior AP; Sucupira A; Florencio R; Tagliari C
    Bone Marrow Transplant; 2006 Apr; 37(8):797-8. PubMed ID: 16518425
    [No Abstract]   [Full Text] [Related]  

  • 6. Increased plasma EPO and MIP-1 alpha are associated with recruitment of vascular progenitors but not CD34(+) cells in autologous peripheral blood stem cell grafts.
    Labonté L; Li Y; Yang L; Gillingham A; Halpenny M; Giulivi A; Sills T; Evans K; Zanke B; Allan DS
    Exp Hematol; 2009 Jun; 37(6):673-8. PubMed ID: 19463769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ideal body weight correlates better with engraftment after PBSC autograft than actual body weight, but is under-estimated in myeloma patients possibly due to disease-related height loss.
    Maclean PS; Parker AN; McQuaker IG; Clark AD; Farrell E; Douglas KW
    Bone Marrow Transplant; 2007 Oct; 40(7):665-9. PubMed ID: 17646841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity related to autologous peripheral blood haematopoietic progenitor cell infusion is associated with number of granulocytes in graft, gender and diagnosis of multiple myeloma.
    Bojanic I; Cepulic BG; Mazic S; Batinic D; Nemet D; Labar B
    Vox Sang; 2008 Jul; 95(1):70-5. PubMed ID: 18422859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of recombinant human erythropoietin therapy started one month after autologous peripheral blood stem cell transplantation.
    Vanstraelen G; Baron F; Frère P; Hafraoui K; Fillet G; Beguin Y
    Haematologica; 2005 Sep; 90(9):1269-70. PubMed ID: 16154851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
    Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
    Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mobilization, collection, and transplantation of peripheral blood hematopoietic progenitor cells in a patient with multiple myeloma and hemoglobin SC disease.
    Tormey CA; Snyder EL; Cooper DL
    Transfusion; 2008 Sep; 48(9):1930-3. PubMed ID: 18513256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythema nodosum secondary to granulocyte colony-stimulating factor in a patient with Hodgkin lymphoma during CD34+ cell mobilization for autologous peripheral blood stem cell transplantation: a dose-mediated effect.
    George S; George B; Gorak E
    Biol Blood Marrow Transplant; 2005 Oct; 11(10):816-7. PubMed ID: 16182183
    [No Abstract]   [Full Text] [Related]  

  • 13. Molecular remission of multiple myeloma with cytoreductive autografting followed by a dose-reduced allograft.
    Fujikawa K; Nakaseko C; Cho R; Abe D; Oda K; Tanaka H; Ohwada C; Ozawa S; Takeuchi M; Sakaida E; Shimizu N; Naito M; Nishimura M; Saito Y
    Bone Marrow Transplant; 2007 Nov; 40(10):997-9. PubMed ID: 17724437
    [No Abstract]   [Full Text] [Related]  

  • 14. Optimal mobilization method and CD34+ dose calculation for autologous PBSC transplant in myeloma patients: two important unresolved questions.
    Alegre A
    Bone Marrow Transplant; 2009 Apr; 43(8):593-5. PubMed ID: 19384344
    [No Abstract]   [Full Text] [Related]  

  • 15. Peripheral blood stem cell collection in multiple myeloma: a retrospective analysis of 6 years leukapheresis activity in 109 patients treated at the Istituto Nazionale dei Tumori of Milan.
    Coluccia P; Montefusco V; Tunesi S; Avella M; Bompadre A; Longoni P; Milanesi M; De Carli A; Ravagnani F
    J Clin Apher; 2009; 24(4):134-40. PubMed ID: 19591198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mobilization of peripheral blood stem cells for autologous transplantation patients with hematological malignancies: Influence of disease, mobilization method, age and sex.
    Zhang C; Chen X; Zhang X; Gao L; Kong P; Wang Q; Peng X; Liu H
    Transfus Apher Sci; 2008 Aug; 39(1):21-8. PubMed ID: 18599353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy.
    Tricot G; Barlogie B; Zangari M; van Rhee F; Hoering A; Szymonifka J; Cottler-Fox M
    Haematologica; 2008 Nov; 93(11):1739-42. PubMed ID: 18728024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple myeloma with concomitant JAK2-positive essential thrombocythemia post-successful autologous peripheral blood hematopoietic stem cell transplant.
    Holtan SG; Hoyer JD; Buadi FK
    Bone Marrow Transplant; 2011 Apr; 46(4):615. PubMed ID: 20581888
    [No Abstract]   [Full Text] [Related]  

  • 19. Unsuccessful stem cell remobilization for autologous transplantation is predicted by renal impairment and a stem cell yield ≤ 0.5 X 10(6) CD34+ cells/kg at first mobilization.
    Hill QA; Pearce R; Cook G
    Bone Marrow Transplant; 2012 Oct; 47(10):1372-3. PubMed ID: 22343671
    [No Abstract]   [Full Text] [Related]  

  • 20. The costs of mobilisation and collection of peripheral blood stem cells in multiple myeloma and lymphoma in an European country: results from The Gruppo Italiano Trapianto Midollo Osseo (GITMO) and Società Italiana di Emaferesi e Manipolazione Cellulare (SIdEM) survey.
    Pierelli L; Berto P; Accorsi P; Milone G; Lopatriello S; Aiello A; Iacopino P; Olivieri A; Rambaldi A; Bosi A
    Transfus Apher Sci; 2013 Dec; 49(3):615-22. PubMed ID: 23973731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.